🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Instant MSC Product accompanying Autologous Chondron Transplantation (IMPACT)

    Disc Medicine

    Symptomatic articular cartilage lesion of the knee (femoral condyles or trochlea)

    phase 3 small molecule active

    1 trial

  2. Insulatard 100 international units/ml suspension for injection in vial., Natriumchloride 0,9% oplossing voor injectie

    Disc Medicine

    Delirium

    phase 3 small molecule active

    1 trial

  3. Insulin Degludec and Insulin Aspart

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Diabetes

    phase 3 small molecule completed

    1 trial

  4. Insulin degludec/insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial

  5. Intermediate-dose Cytarabine in Combination with Venetoclax

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

  6. Intervention

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV

    phase 3 other active

    1 trial

  7. Intervention - a validated home BP monitor and support from the specialist nurse

    United Therapeutics Europe Ltd

    Stroke

    phase 3 other completed

    1 trial

  8. Intra-arterial thrombolysis

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 3 other active

    1 trial

  9. Intranasal Fentanyl Spray (INFS)

    Takeda

    Break Through Pain

    phase 3 small molecule completed

    1 trial

  10. Intravenous methylene blue administration

    Hospital Authority, Hong Kong

    Severe Sepsis

    phase 3 small molecule active

    1 trial

  11. Intravenous nicardipine hydrochloride

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Intracerebral Hemorrhage

    phase 3 small molecule terminated

    1 trial

  12. Intravenous rhTNK-tPA

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stroke, Acute Ischemic

    phase 3 small molecule active

    1 trial

  13. Intravenous thrombolysis plus tirofiban

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 3 small molecule completed

    1 trial

  14. Intravenous thrombolysis plus tirofiban

    Hospital Authority, Hong Kong

    Acute Ischemic Stroke

    phase 3 small molecule completed

    1 trial

  15. Irinotecan Accord, 20 mg/ml, koncentrat do sporządzania roztworu do infuzji, Bendadocel 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cyramza 10 mg/ml concentrate for solution for

    AstraZeneca AB

    Gastric cancer, Advanced/Metastatic Gastric cancer, Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

    phase 3 small molecule active

    1 trial

  16. JEVTANA 60 mg concentrate and solvent for solution for infusion.

    Ningbo Cancer Hospital

    Patients with localized prostate cancer and high-risk features of relapse.

    phase 3 small molecule active

    1 trial

  17. JNJ-56021927

    Ningbo Cancer Hospital

    High-risk biochemically-relapsed prostate adenocarcinoma following radical prostatectomy.

    phase 3 small molecule active

    1 trial

  18. JNJ-63723283, JNJ-63723283, Gemcitabina Accord 100 mg/ml concentrato per soluzione per infusione., JNJ-17000139, GEMCITABINE ACCORD 100 mg/ml, solution à diluer pour perfusion, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Gemcitabine100 mg/ml Concentrate for Solution for Infusion, Gemcitabin Accord 100 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Janssen-Cilag International N.V.

    Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder

    phase 3 small molecule active

    1 trial

  19. JNJ-75276617, Venclyxto 100 mg film-coated tablets, matching the 100 mg (G030), matching the 30 mg (G031), Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, JNJ-75276617, JNJ-75276617, matching the 50 mg (G029), JNJ-75276617, Azacitidine betapharm 25 mg/mL powder for suspension for injection

    Janssen-Cilag International N.V.

    Acute Myeloid Luekemia

    phase 3 small molecule active

    1 trial

  20. Jianpi Lishi Jiedu Granules

    The First People's Hospital of Lianyungang

    Colorectal Adenoma

    phase 3 small molecule active

    1 trial

  21. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Ningbo Cancer Hospital

    High risk resected melanoma.

    phase 3 small molecule active

    1 trial

  22. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ADSTILADRIN, GEMCITABINE , DOCETAXEL

    Ferring Pharmaceuticals

    High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ(CIS) with or without papillary tumours

    phase 3 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion, BI 1810631, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Boehringer Ingelheim

    non-squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion, GEMCITABINE , ENFORTUMAB VEDOTIN , CISPLATIN

    Merck Sharp and Dohme

    Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources